ライフサイエンスコーパス: nefazodone

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 pears to be efficacious for nonresponders to nefazodone, and nefazodone appears to be effective for C

2 In addition, trovafloxacin, nefazodone, and ritonavir were reported to be associated

3 RI) antidepressants (bupropion, mirtazapine, nefazodone, and venlafaxine), tricyclic antidepressants,

4 cacious for nonresponders to nefazodone, and nefazodone appears to be effective for CBASP nonresponde

5 when they are administered with fluvoxamine, nefazodone, fluoxetine, and sertraline.

6 the rates of response were 55 percent in the nefazodone group and 52 percent in the psychotherapy gro

7 pped out of the study prematurely, 22 in the nefazodone group and 8 in the CBASP group.

8 factory response) was 48 percent in both the nefazodone group and in the psychotherapy group, as comp

9 Adverse events in the nefazodone group were consistent with the known side eff

10 new-generation non-SSRI antidepressants (eg, nefazodone hydrochloride, mirtazapine, bupropion hydroch

11 Nefazodone is a weaker serotonin and norepinephrine reup

12 der to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive

13 have been recently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine.

14 lopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and v

15 response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of

16 ater risks of hepatotoxicity are iproniazid, nefazodone, phenelzine, imipramine, amitriptyline, dulox

17 e to CBASP and the switch from from CBASP to nefazodone resulted in clinically and statistically sign

18 Because nefazodone seems to cause severe hepatocellular injury i

19 mistries should be performed before starting nefazodone therapy and patients should be monitored regu

20 temporal onset of disease after the start of nefazodone therapy suggested severe hepatocellular injur

21 However, the switch to CBASP following nefazodone therapy was associated with significantly les

22 at sample revealed that both the switch from nefazodone to CBASP and the switch from from CBASP to ne

23 ts (selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participant

24 The dosage of nefazodone was 100 to 600 mg/d; CBASP was provided twice

25 Nefazodone was administered for 14 to 28 weeks before th

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。